三羧酸循环模式转换决定套细胞淋巴瘤中pirtobrutinib耐受持留细胞的命运
该研究利用美国食品药品监督管理局近期批准的非共价BTK抑制剂pirtobrutinib,在套细胞淋巴瘤中鉴定出具有形态可变性的pirtobrutinib耐受持留细胞,表现为可逆命运转换的增大细胞(巨细胞)群体。巨细胞进入非增殖、去分化状态,依赖活化的胞质三羧酸循环偶联苹果酸-天冬氨酸穿梭进行生物合成;药物去除后三羧酸循环转向氧化分解代谢,促使巨细胞分化为常规大小细胞。乙酰辅酶A通过微调干性调控细胞命运,双相模型表明代谢转换决定持留细胞的表型可塑性,在巨细胞分化前靶向巨细胞是克服套细胞淋巴瘤治疗耐药的有前景策略。
要点
- pirtobrutinib耐受持留细胞呈现增大细胞(巨细胞)群体,具有可逆的命运转换。
- 巨细胞依赖活化的胞质三羧酸循环偶联苹果酸-天冬氨酸穿梭进行生物合成。
- 药物去除后三羧酸循环转向氧化分解代谢,促使巨细胞分化为常规大小细胞。
核心结论
- 双相模型表明代谢转换调控套细胞淋巴瘤中药物耐受持留细胞的表型可塑性,在巨细胞分化前靶向巨细胞是克服治疗耐药的有前景策略。
研究设计与样本
- 研究使用非共价BTK抑制剂pirtobrutinib在套细胞淋巴瘤中鉴定药物耐受持留细胞并对其代谢与命运转换进行表征。
主要发现
- pirtobrutinib耐受持留细胞呈现形态可变性,表现为具有可逆命运转换的增大细胞(巨细胞)群体。
- 治疗期间巨细胞进入非增殖、去分化状态,依赖活化的胞质三羧酸循环偶联苹果酸-天冬氨酸穿梭进行生物合成。
- 药物去除后三羧酸循环转向氧化分解代谢,促使巨细胞分化为常规大小细胞。
- 整个转换过程中乙酰辅酶A通过微调干性调控细胞命运。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bruton tyrosine kinase inhibitors (BTKis) and cell therapy have successfully been used to treat mantle cell lymphoma (MCL). However, therapy resistance inevitably emerges. Cancer cells can progressively develop stable resistance by traversing through a transient drug-tolerant persister (DTP) state. The mechanisms enabling DTP cells to reversibly adapt to therapies and evolve to acquire heterogeneity remain poorly understood, and characterizing DTP cells in MCL continues to pose a challenge for clinic translation. Here, using pirtobrutinib, a recently US Food and Drug Administration-approved noncovalent BTKi, we identified pirtobrutinib-tolerant persister cells exhibiting morphological variability by presenting a unique population of enlarged cells (giant cells) with reversible fate transitions. During treatment, giant cells enter a nonproliferative, dedifferentiated state, addicted to an activated cytosolic tricarboxylic acid (TCA) cycle coupled with the malate-aspartate shuttle to engage in biosynthesis. Upon drug removal, the TCA cycle shifts to oxidative catabolism, promoting giant cells to differentiate into regular-sized cells. Throughout the transition, acetyl coenzyme A modulates cell fate by fine-tuning stemness. Our biphasic model demonstrates that the metabolic switch governs the phenotypic plasticity of DTP cells in MCL, resulting in a dynamic presence of DTP cells across various developmental states in response to systemic therapies. Targeting giant cells before their differentiation offers a promising strategy to overcoming therapy resistance in MCL.
引用
- Wang W, Cai Q, Liu Y, et al. TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma. Blood. 2025. PMID: 40700581. doi:10.1182/blood.2024026919
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。